Tian Yao, Yi Jiacai, Wang Ningning, Wu Chengkun, Peng Jinfu, Liu Shao, Yang Guoping, Cao Dongsheng
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, P.R. China.
School of Computer Science, National University of Defense Technology, Changsha, Hunan 410073, P.R. China.
Nucleic Acids Res. 2025 Jan 6;53(D1):D1356-D1362. doi: 10.1093/nar/gkae726.
Drug interactions pose significant challenges in clinical practice, potentially leading to adverse drug reactions, reduced efficacy, and even life-threatening consequences. As polypharmacy becomes increasingly common, the risk of harmful drug interactions rises, underscoring the need for comprehensive and user-friendly drug interaction resources to ensure patient safety. To address these concerns and support healthcare professionals in optimizing drug therapy, we present DDInter 2.0, a significantly expanded and enhanced update to our drug interaction database. This new version incorporates additional interaction types, including drug-food interactions (DFIs), drug-disease interactions (DDSIs), and therapeutic duplications, providing a more complete resource for clinical decision-making. The updated database covers 2310 drugs, with 302 516 drug-drug interaction (DDI) records accompanied by 8398 distinct, high-quality mechanism descriptions and management recommendations. DDInter 2.0 also includes 857 DFIs, 8359 DDSIs and 6033 therapeutic duplication records, each supplemented with detailed information and guidance. Furthermore, the enhanced user interface and advanced filtering options in this second release facilitate easy access to and analysis of the comprehensive drug interaction data. By providing healthcare professionals and researchers with a more complete and user-friendly resource, DDInter 2.0 aims to support clinical decision-making and ultimately improve patient outcomes. DDInter 2.0 is freely accessible at https://ddinter2.scbdd.com.
药物相互作用在临床实践中带来了重大挑战，可能导致药物不良反应、疗效降低，甚至危及生命的后果。随着联合用药越来越普遍，有害药物相互作用的风险增加，这凸显了需要全面且用户友好的药物相互作用资源以确保患者安全。为了解决这些问题并支持医疗保健专业人员优化药物治疗，我们推出了DDInter 2.0，这是我们药物相互作用数据库的一次显著扩展和增强的更新版本。这个新版本纳入了更多的相互作用类型，包括药物-食物相互作用（DFI）、药物-疾病相互作用（DDSI）和治疗重复，为临床决策提供了更完整的资源。更新后的数据库涵盖2310种药物，有302516条药物-药物相互作用（DDI）记录，并伴有8398条独特的、高质量的作用机制描述和管理建议。DDInter 2.0还包括857条DFI、8359条DDSI和6033条治疗重复记录，每条记录都补充了详细信息和指导。此外，此第二版增强的用户界面和高级筛选选项便于轻松访问和分析全面的药物相互作用数据。通过为医疗保健专业人员和研究人员提供更完整且用户友好的资源，DDInter 2.0旨在支持临床决策并最终改善患者预后。可通过https://ddinter2.scbdd.com免费访问DDInter 2.0。
